@article{baf1d486625f4f119184a4621c45e819,
title = "The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study",
abstract = "Introduction: Motoric cognitive risk (MCR), a clinical syndrome characterized by slow gait speed and subjective cognitive complaints, has been associated with dementia risk. The neuropathological features underlying MCR remain poorly understood. Methods: The Atherosclerosis Risk in Communities (ARIC) community-based cohort study classified participants using standardized criteria as MCR+/– and mild cognitive impairment (MCI)+/– at study baseline (2011–2013). We examined the 5-year dementia risk and baseline brain structural/molecular abnormalities associated with MCR+ and MCI+ status. Results: Of 5023 nondemented participants included, 204 were MCR+ and 1030 were MCI+. Both MCR+ and MCI+ participants demonstrated increased dementia risk. The pattern of structural brain abnormalities associated with MCR+ differed from that of MCI+. Whereas MCI+ was associated with comparatively smaller volumes in brain regions vulnerable to Alzheimer's disease pathology, MCR+ status was associated with smaller volumes in frontoparietal regions and greater white matter abnormalities. Discussion: MCR may represent a predementia syndrome characterized by prominent white matter abnormalities and frontoparietal atrophy.",
keywords = "brain volume, dementia, gait speed, motoric cognitive risk, white matter",
author = "Gomez, {Gabriela T.} and Gottesman, {Rebecca F.} and Gabriel, {Kelley Pettee} and Priya Palta and Gross, {Alden L.} and Anja Soldan and Albert, {Marilyn S.} and Sullivan, {Kevin J.} and Jack, {Clifford R.} and Knopman, {David S.} and Windham, {B. Gwen} and Walker, {Keenan A.}",
note = "Funding Information: GG, RG, KPG, PP, AG, AS, KS, BGW, and KAW: no conflicts to report. RG: former associate editor for the journal . CJ: serves on an independent data monitoring board for Roche and has consulted for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. DK: served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety monitoring Board for a tau therapeutic for Biogen but receives no personal compensation. He is a site investigator in the Biogen aducanumab trials. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Roche, and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. Neurology Funding Information: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). Neurocognitive data are collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01‐HL70825 from the NHLBI. The authors thank the staff and participants of the ARIC study for their important contributions. The ARIC‐PET study is funded by the National Institute on Aging (R01AG040282). Infrastructure was partially supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This study was also supported by contracts K23 AG064122 (Dr. Walker) and K24 AG052573 (Dr. Gottesman) from NIA. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, as well as by the William Walker Award, the Dean's Summer Research Fund, and the Paul McHugh Program for Human Flourishing at the Johns Hopkins University School of Medicine. Avid Radiopharmaceuticals provided the florbetapir isotope for the study but had no role in the study design or interpretation of results. Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",
year = "2021",
doi = "10.1002/alz.12412",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
}